Cetuximab (Erbitux®), a monoclonal antibody targeting EGFR, is currently used in EGFR-expressing metastatic colorectal cancer (mCRC) in combination with cytotoxic chemotherapy (irinotecan), after failure of a previous irinotecan-based regimen. Here, EGFR is linked to metastatic colorectal cancer.